Recursion Pharmaceuticals's total assets for Q1 2025 were $1.31B, a decrease of -9.90% from the previous quarter. RXRX total liabilities were $371.29M for the fiscal quarter, a -10.28% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.